drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00374 | DB09038 | 1,061 | 1,450 | [
"DDInter1852",
"DDInter636"
] | Treprostinil | Empagliflozin | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1061,
24,
1450
]
],
[
[
1061,
63,
461
],
[
461,
24,
1450
]
],
[
[
1061,
24,
1605
],
[
1605,
24,
1450
]
],
[
[
1061,
1,
885
],
[
885,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indap... |
DB00193 | DB09065 | 534 | 760 | [
"DDInter1841",
"DDInter424"
] | Tramadol | Cobicistat | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
534,
24,
760
]
],
[
[
534,
24,
1374
],
[
1374,
23,
760
]
],
[
[
534,
25,
868
],
[
868,
24,
760
]
],
[
[
534,
24,
609
],
[
609,
2... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Tramadol may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a ... |
DB09046 | DB14881 | 1,094 | 180 | [
"DDInter1201",
"DDInter1329"
] | Metreleptin | Oliceridine | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1094,
24,
180
]
],
[
[
1094,
24,
124
],
[
124,
24,
180
]
],
[
[
1094,
63,
578
],
[
578,
24,
180
]
],
[
[
1094,
24,
741
],
[
741,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticag... |
DB01230 | DB09122 | 795 | 1,613 | [
"DDInter1416",
"DDInter1409"
] | Pemoline | Peginterferon beta-1a | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
795,
24,
1613
]
],
[
[
795,
63,
1503
],
[
1503,
24,
1613
]
],
[
[
795,
24,
1383
],
[
1383,
63,
1613
]
],
[
[
795,
24,
850
],
[
850,
... | [
[
[
"Pemoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Pemoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
... | Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and S... |
DB00978 | DB00987 | 739 | 1,224 | [
"DDInter1084",
"DDInter460"
] | Lomefloxacin | Cytarabine | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Minor | 0 | [
[
[
739,
23,
1224
]
],
[
[
739,
6,
3199
],
[
3199,
57,
1224
]
],
[
[
739,
1,
872
],
[
872,
62,
1224
]
],
[
[
739,
1,
1467
],
[
1467,
... | [
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) binds {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Com... | Lomefloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Cytarabine (Compound)
Lomefloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Lomefloxacin (Compound) resembles Enoxacin (Compound) ... |
DB01142 | DB04953 | 1,264 | 495 | [
"DDInter593",
"DDInter708"
] | Doxepin | Ezogabine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
1264,
24,
495
]
],
[
[
1264,
21,
28997
],
[
28997,
60,
495
]
],
[
[
1264,
62,
112
],
[
112,
23,
495
]
],
[
[
1264,
64,
1494
],
[
1494,... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Doxepin",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u} (Side ... | Doxepin (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Ezogabine (Compound)
Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when t... |
DB00658 | DB01022 | 965 | 1,484 | [
"DDInter1663",
"DDInter1461"
] | Sevelamer | Phylloquinone | Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel. | Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders d... | Moderate | 1 | [
[
[
965,
24,
1484
]
],
[
[
965,
63,
1461
],
[
1461,
40,
1484
]
],
[
[
965,
21,
28719
],
[
28719,
60,
1484
]
],
[
[
965,
63,
1461
],
[
1461... | [
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phylloquinone"
]
],
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Sevelamer may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E (Compound) resembles Phylloquinone (Compound)
Sevelamer (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Phylloquinone (Compound)
Sevelamer may cause a moderate interaction that coul... |
DB00193 | DB01075 | 534 | 1,376 | [
"DDInter1841",
"DDInter569"
] | Tramadol | Diphenhydramine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
534,
24,
1376
]
],
[
[
534,
24,
649
],
[
649,
63,
1376
]
],
[
[
534,
25,
11
],
[
11,
1,
1376
]
],
[
[
534,
24,
128
],
[
128,
24,... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Tramadol may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound... |
DB09073 | DB14723 | 951 | 159 | [
"DDInter1379",
"DDInter1026"
] | Palbociclib | Larotrectinib | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
951,
24,
159
]
],
[
[
951,
23,
907
],
[
907,
23,
159
]
],
[
[
951,
62,
479
],
[
479,
23,
159
]
],
[
[
951,
24,
1375
],
[
1375,
2... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Palbociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[... | Palbociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezi... |
DB06691 | DB09420 | 849 | 1,074 | [
"DDInter1155",
"DDInter953"
] | Mepyramine | Iodide I-123 | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
849,
24,
1074
]
],
[
[
849,
63,
516
],
[
516,
24,
1074
]
],
[
[
849,
74,
100
],
[
100,
24,
1074
]
],
[
[
849,
24,
1399
],
[
1399,
... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interac... |
DB06343 | DB09564 | 1,379 | 1,296 | [
"DDInter1766",
"DDInter930"
] | Teprotumumab | Insulin degludec | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1379,
24,
1296
]
],
[
[
1379,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
1379,
24,
52
],
[
52,
24,
1296
]
],
[
[
1379,
24,
1385
],
[
1385,
... | [
[
[
"Teprotumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Teprotumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Teprotumumab may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Teprotumumab may cause a moderate interaction that could exacerbate diseases when taken with Dulagluti... |
DB01263 | DB08881 | 859 | 868 | [
"DDInter1494",
"DDInter1925"
] | Posaconazole | Vemurafenib | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
859,
25,
868
]
],
[
[
859,
6,
8374
],
[
8374,
45,
868
]
],
[
[
859,
21,
29015
],
[
29015,
60,
868
]
],
[
[
859,
63,
608
],
[
608,
... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Posaconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ve... | Posaconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Posaconazole (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Lidoc... |
DB00361 | DB09330 | 134 | 985 | [
"DDInter1939",
"DDInter1352"
] | Vinorelbine | Osimertinib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
134,
24,
985
]
],
[
[
134,
63,
168
],
[
168,
23,
985
]
],
[
[
134,
24,
112
],
[
112,
23,
985
]
],
[
[
134,
24,
1478
],
[
1478,
2... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Me... |
DB00783 | DB09065 | 1,438 | 760 | [
"DDInter679",
"DDInter424"
] | Estradiol | Cobicistat | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1438,
24,
760
]
],
[
[
1438,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1438,
63,
723
],
[
723,
24,
760
]
],
[
[
1438,
24,
868
],
[
868,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant... |
DB01601 | DB09080 | 833 | 144 | [
"DDInter1089",
"DDInter1331"
] | Lopinavir | Olodaterol | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to ... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
833,
24,
144
]
],
[
[
833,
25,
1011
],
[
1011,
24,
144
]
],
[
[
833,
64,
57
],
[
57,
24,
144
]
],
[
[
833,
63,
600
],
[
600,
24,... | [
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Lopinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",... | Lopinavir may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Lopinavir may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a mod... |
DB00357 | DB12001 | 1,051 | 564 | [
"DDInter71",
"DDInter7"
] | Aminoglutethimide | Abemaciclib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
1051,
24,
564
]
],
[
[
1051,
24,
868
],
[
868,
24,
564
]
],
[
[
1051,
62,
1101
],
[
1101,
24,
564
]
],
[
[
1051,
24,
159
],
[
159,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bexaro... |
DB01182 | DB06663 | 371 | 1,154 | [
"DDInter1534",
"DDInter1398"
] | Propafenone | Pasireotide | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
371,
25,
1154
]
],
[
[
371,
63,
966
],
[
966,
40,
1154
]
],
[
[
371,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
371,
62,
112
],
[
112,
... | [
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreot... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Propafenone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Propafenone may cause a minor ... |
DB08880 | DB12015 | 1,510 | 1,033 | [
"DDInter1771",
"DDInter53"
] | Teriflunomide | Alpelisib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1510,
24,
1033
]
],
[
[
1510,
25,
738
],
[
738,
24,
1033
]
],
[
[
1510,
63,
1144
],
[
1144,
24,
1033
]
],
[
[
1510,
64,
322
],
[
322,
... | [
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
],
[
"Nirapa... | Teriflunomide may lead to a major life threatening interaction when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may c... |
DB00067 | DB08875 | 317 | 1,618 | [
"DDInter1921",
"DDInter262"
] | Vasopressin | Cabozantinib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
317,
25,
1618
]
],
[
[
317,
23,
112
],
[
112,
23,
1618
]
],
[
[
317,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
317,
24,
480
],
[
480,
... | [
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric ac... |
DB00975 | DB06081 | 1,317 | 1,046 | [
"DDInter573",
"DDInter286"
] | Dipyridamole | Caplacizumab | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
1317,
25,
1046
]
],
[
[
1317,
23,
1631
],
[
1631,
62,
1046
]
],
[
[
1317,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
1317,
63,
1171
],
[
11... | [
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Dipyridamole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric... | Dipyridamole may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dex... |
DB00005 | DB04865 | 1,057 | 4 | [
"DDInter687",
"DDInter1335"
] | Etanercept | Omacetaxine mepesuccinate | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
1057,
25,
4
]
],
[
[
1057,
25,
1394
],
[
1394,
24,
4
]
],
[
[
1057,
25,
994
],
[
994,
63,
4
]
],
[
[
1057,
24,
496
],
[
496,
63,... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rituximab"
],
[
"Rituximab",... | Etanercept may lead to a major life threatening interaction when taken with Rituximab and Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Etanercept may lead to a major life threatening interaction when taken with Risankizumab and Risankizumab may caus... |
DB01276 | DB14731 | 123 | 1,518 | [
"DDInter706",
"DDInter1741"
] | Exenatide | Tagraxofusp | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
123,
24,
1518
]
],
[
[
123,
63,
176
],
[
176,
24,
1518
]
],
[
[
123,
24,
850
],
[
850,
24,
1518
]
],
[
[
123,
63,
695
],
[
695,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Brentuxima... |
DB01211 | DB11901 | 609 | 913 | [
"DDInter393",
"DDInter107"
] | Clarithromycin | Apalutamide | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
609,
24,
913
]
],
[
[
609,
64,
312
],
[
312,
23,
913
]
],
[
[
609,
62,
112
],
[
112,
23,
913
]
],
[
[
609,
23,
271
],
[
271,
23,... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"E... | Clarithromycin may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole... |
DB00365 | DB01181 | 839 | 1,532 | [
"DDInter842",
"DDInter906"
] | Grepafloxacin | Ifosfamide | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
839,
24,
1532
]
],
[
[
839,
62,
1648
],
[
1648,
24,
1532
]
],
[
[
839,
25,
351
],
[
351,
63,
1532
]
],
[
[
839,
25,
401
],
[
401,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aldesleukin"
],
... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Grepafloxacin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may ... |
DB06605 | DB13148 | 1,409 | 1,566 | [
"DDInter108",
"DDInter422"
] | Apixaban | Coagulation factor X human | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency. However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe here... | Moderate | 1 | [
[
[
1409,
24,
1566
]
],
[
[
1409,
64,
553
],
[
553,
24,
1566
]
],
[
[
1409,
25,
1421
],
[
1421,
24,
1566
]
],
[
[
1409,
64,
553
],
[
553,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Coagulation factor X human"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
... | Apixaban may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Coagulation factor X human
Apixaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause... |
DB05294 | DB12245 | 1,069 | 823 | [
"DDInter1917",
"DDInter1863"
] | Vandetanib | Triclabendazole | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
1069,
25,
823
]
],
[
[
1069,
62,
1247
],
[
1247,
23,
823
]
],
[
[
1069,
25,
1612
],
[
1612,
24,
823
]
],
[
[
1069,
64,
1010
],
[
1010,... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Vandetanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Vandetanib may lead to a major life threatening interaction when taken with Fostemsavir and Fostems... |
DB00365 | DB01105 | 839 | 222 | [
"DDInter842",
"DDInter1665"
] | Grepafloxacin | Sibutramine | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Minor | 0 | [
[
[
839,
23,
222
]
],
[
[
839,
24,
384
],
[
384,
62,
222
]
],
[
[
839,
64,
600
],
[
600,
23,
222
]
],
[
[
839,
25,
609
],
[
609,
62,... | [
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Grepafloxacin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may... |
DB00570 | DB09330 | 147 | 985 | [
"DDInter1936",
"DDInter1352"
] | Vinblastine | Osimertinib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
147,
24,
985
]
],
[
[
147,
63,
168
],
[
168,
23,
985
]
],
[
[
147,
24,
112
],
[
112,
23,
985
]
],
[
[
147,
24,
1478
],
[
1478,
2... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Me... |
DB00792 | DB00794 | 832 | 759 | [
"DDInter1878",
"DDInter1521"
] | Tripelennamine | Primidone | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
832,
24,
759
]
],
[
[
832,
24,
697
],
[
697,
40,
759
]
],
[
[
832,
63,
362
],
[
362,
1,
759
]
],
[
[
832,
24,
401
],
[
401,
63,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (... |
DB01166 | DB01246 | 477 | 820 | [
"DDInter379",
"DDInter45"
] | Cilostazol | Alimemazine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
477,
24,
820
]
],
[
[
477,
63,
1335
],
[
1335,
24,
820
]
],
[
[
477,
63,
675
],
[
675,
25,
820
]
],
[
[
477,
63,
508
],
[
508,
1... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyp... |
DB00572 | DB01242 | 85 | 1,237 | [
"DDInter136",
"DDInter410"
] | Atropine | Clomipramine | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
85,
24,
1237
]
],
[
[
85,
24,
684
],
[
684,
1,
1237
]
],
[
[
85,
24,
272
],
[
272,
24,
1237
]
],
[
[
85,
24,
146
],
[
146,
40,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interact... |
DB00374 | DB00808 | 1,061 | 1,605 | [
"DDInter1852",
"DDInter916"
] | Treprostinil | Indapamide | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
1061,
24,
1605
]
],
[
[
1061,
24,
811
],
[
811,
1,
1605
]
],
[
[
1061,
21,
28640
],
[
28640,
60,
1605
]
],
[
[
1061,
24,
126
],
[
126,... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Treprostinil (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Indapamide (Compound)
Treprostinil may cause a moderate inte... |
DB00250 | DB12010 | 10 | 214 | [
"DDInter475",
"DDInter785"
] | Dapsone | Fostamatinib | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
10,
24,
214
]
],
[
[
10,
24,
723
],
[
723,
24,
214
]
],
[
[
10,
23,
307
],
[
307,
24,
214
]
],
[
[
10,
24,
179
],
[
179,
63,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dapsone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may... |
DB00005 | DB00635 | 1,057 | 1,573 | [
"DDInter687",
"DDInter1515"
] | Etanercept | Prednisone | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Major | 2 | [
[
[
1057,
25,
1573
]
],
[
[
1057,
25,
175
],
[
175,
40,
1573
]
],
[
[
1057,
25,
251
],
[
251,
1,
1573
]
],
[
[
1057,
24,
1382
],
[
1382,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
... | Etanercept may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Etanercept may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (Compound)
Etanercept may cau... |
DB00366 | DB00662 | 1,594 | 717 | [
"DDInter600",
"DDInter1873"
] | Doxylamine | Trimethobenzamide | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1594,
24,
717
]
],
[
[
1594,
21,
28921
],
[
28921,
60,
717
]
],
[
[
1594,
24,
1382
],
[
1382,
63,
717
]
],
[
[
1594,
24,
109
],
[
109,... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) ... | Doxylamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Trimethobenzamide (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Tr... |
DB00501 | DB00813 | 752 | 704 | [
"DDInter380",
"DDInter722"
] | Cimetidine | Fentanyl | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Moderate | 1 | [
[
[
752,
24,
704
]
],
[
[
752,
23,
307
],
[
307,
1,
704
]
],
[
[
752,
63,
194
],
[
194,
40,
704
]
],
[
[
752,
25,
543
],
[
543,
1,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fentanyl (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Cimeti... |
DB00907 | DB06262 | 290 | 1,354 | [
"DDInter427",
"DDInter606"
] | Cocaine (topical) | Droxidopa | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a def... | Major | 2 | [
[
[
290,
25,
1354
]
],
[
[
290,
25,
584
],
[
584,
40,
1354
]
],
[
[
290,
25,
1148
],
[
1148,
24,
1354
]
],
[
[
290,
6,
7390
],
[
7390,
... | [
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droxidopa"
]
],
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levonordefrin"
],
[
"Levonordefrin",
"{u} (C... | Cocaine may lead to a major life threatening interaction when taken with Droxidopa
Cocaine may lead to a major life threatening interaction when taken with Levonordefrin and Levonordefrin (Compound) resembles Droxidopa (Compound)
Cocaine may lead to a major life threatening interaction when taken with Isoprenaline and ... |
DB00601 | DB00748 | 453 | 662 | [
"DDInter1073",
"DDInter297"
] | Linezolid | Carbinoxamine | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
453,
24,
662
]
],
[
[
453,
64,
1594
],
[
1594,
24,
662
]
],
[
[
453,
63,
128
],
[
128,
24,
662
]
],
[
[
453,
21,
28921
],
[
28921,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxylamine"
],
[
"Doxylamin... | Linezolid may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheni... |
DB01191 | DB08816 | 1,039 | 578 | [
"DDInter518",
"DDInter1802"
] | Dexfenfluramine | Ticagrelor | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1039,
24,
578
]
],
[
[
1039,
24,
271
],
[
271,
62,
578
]
],
[
[
1039,
63,
1578
],
[
1578,
24,
578
]
],
[
[
1039,
24,
868
],
[
868,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
]... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and... |
DB00261 | DB00831 | 702 | 1,178 | [
"DDInter93",
"DDInter1866"
] | Anagrelide | Trifluoperazine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Major | 2 | [
[
[
702,
25,
1178
]
],
[
[
702,
25,
695
],
[
695,
40,
1178
]
],
[
[
702,
25,
9
],
[
9,
1,
1178
]
],
[
[
702,
6,
7950
],
[
7950,
45,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u... | Anagrelide may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Trifluoperazine (Compound)
Anagreli... |
DB00641 | DB13873 | 467 | 1,534 | [
"DDInter1675",
"DDInter719"
] | Simvastatin | Fenofibric acid | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Major | 2 | [
[
[
467,
25,
1534
]
],
[
[
467,
24,
267
],
[
267,
24,
1534
]
],
[
[
467,
63,
372
],
[
372,
24,
1534
]
],
[
[
467,
25,
384
],
[
384,
... | [
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Nal... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine an... |
DB00563 | DB00580 | 663 | 311 | [
"DDInter1174",
"DDInter1910"
] | Methotrexate | Valdecoxib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Moderate | 1 | [
[
[
663,
24,
311
]
],
[
[
663,
63,
1560
],
[
1560,
24,
311
]
],
[
[
663,
24,
1272
],
[
1272,
63,
311
]
],
[
[
663,
25,
1512
],
[
1512,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine a... |
DB00365 | DB00570 | 839 | 147 | [
"DDInter842",
"DDInter1936"
] | Grepafloxacin | Vinblastine | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
839,
24,
147
]
],
[
[
839,
62,
134
],
[
134,
24,
147
]
],
[
[
839,
23,
970
],
[
970,
23,
147
]
],
[
[
839,
23,
37
],
[
37,
62,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinorelbine"
],
... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fluorouracil and... |
DB00620 | DB14444 | 175 | 151 | [
"DDInter1855",
"DDInter924"
] | Triamcinolone | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
175,
24,
151
]
],
[
[
175,
63,
66
],
[
66,
24,
151
]
],
[
[
175,
24,
1619
],
[
1619,
24,
151
]
],
[
[
175,
40,
1573
],
[
1573,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that c... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Triamcinolone may cause a moderate... |
DB09049 | DB15093 | 1,135 | 1,654 | [
"DDInter1261",
"DDInter1698"
] | Naloxegol | Somapacitan | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1135,
24,
1654
]
],
[
[
1135,
25,
351
],
[
351,
24,
1654
]
],
[
[
1135,
62,
1250
],
[
1250,
24,
1654
]
],
[
[
1135,
24,
1499
],
[
1499... | [
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Naloxegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib"... | Naloxegol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Pazopanib and Pazopanib may cause a mod... |
DB00501 | DB00599 | 752 | 682 | [
"DDInter380",
"DDInter1795"
] | Cimetidine | Thiopental | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | Minor | 0 | [
[
[
752,
23,
682
]
],
[
[
752,
62,
1023
],
[
1023,
1,
682
]
],
[
[
752,
6,
8374
],
[
8374,
45,
682
]
],
[
[
752,
63,
475
],
[
475,
2... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thiopental"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentobarbital"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Pentobarbital and Pentobarbital (Compound) resembles Thiopental (Compound)
Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Thiopental (Compound)
Cimetidine may cause a moderate interaction that could exacerb... |
DB00691 | DB00731 | 1,058 | 1,144 | [
"DDInter1237",
"DDInter1269"
] | Moexipril | Nateglinide | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
1058,
24,
1144
]
],
[
[
1058,
1,
11483
],
[
11483,
40,
1144
]
],
[
[
1058,
40,
766
],
[
766,
1,
1144
]
],
[
[
1058,
40,
610
],
[
610,
... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Spirapril"
],
[
"Spirapril",
"{u} (Compound) resembles {... | Moexipril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Nateglinide (Compound)
Moexipril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Nateglinide (Compound)
Moexipril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction tha... |
DB00322 | DB01155 | 141 | 872 | [
"DDInter742",
"DDInter813"
] | Floxuridine | Gemifloxacin | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Minor | 0 | [
[
[
141,
23,
872
]
],
[
[
141,
23,
739
],
[
739,
1,
872
]
],
[
[
141,
23,
945
],
[
945,
40,
872
]
],
[
[
141,
62,
1176
],
[
1176,
1,... | [
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Floxuridine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (... |
DB00524 | DB11827 | 811 | 433 | [
"DDInter1199",
"DDInter669"
] | Metolazone | Ertugliflozin | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
811,
24,
433
]
],
[
[
811,
24,
959
],
[
959,
24,
433
]
],
[
[
811,
63,
251
],
[
251,
24,
433
]
],
[
[
811,
40,
1014
],
[
1014,
2... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Be... |
DB00370 | DB09020 | 1,251 | 28 | [
"DDInter1230",
"DDInter212"
] | Mirtazapine | Bisacodyl | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1251,
24,
28
]
],
[
[
1251,
24,
662
],
[
662,
1,
28
]
],
[
[
1251,
24,
128
],
[
128,
40,
28
]
],
[
[
1251,
18,
10699
],
[
10699,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Bisacodyl (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine (Compound) resembles... |
DB00603 | DB00705 | 303 | 441 | [
"DDInter1137",
"DDInter496"
] | Medroxyprogesterone acetate | Delavirdine | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Minor | 0 | [
[
[
303,
23,
441
]
],
[
[
303,
6,
8374
],
[
8374,
45,
441
]
],
[
[
303,
21,
29323
],
[
29323,
60,
441
]
],
[
[
303,
24,
868
],
[
868,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delavirdine"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (G... | Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Delavirdine (Compound)
Medroxyprogesterone acetate (Compound) causes Paralysis (Side Effect) and Paralysis (Side Effect) is caused by Delavirdine (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could ex... |
DB05294 | DB11057 | 1,069 | 720 | [
"DDInter1917",
"DDInter1223"
] | Vandetanib | Mineral oil | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1069,
24,
720
]
],
[
[
1069,
25,
927
],
[
927,
63,
720
]
],
[
[
1069,
64,
1151
],
[
1151,
24,
720
]
],
[
[
1069,
63,
898
],
[
898,
... | [
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafe... | Vandetanib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Vandetanib may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate int... |
DB00474 | DB01168 | 1,269 | 1,053 | [
"DDInter1173",
"DDInter1526"
] | Methohexital | Procarbazine | An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1269,
24,
1053
]
],
[
[
1269,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1269,
25,
126
],
[
126,
23,
1053
]
],
[
[
1269,
63,
1648
],
[
16... | [
[
[
"Methohexital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Methohexital",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is ... | Methohexital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Methohexital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Methohexita... |
DB00704 | DB13179 | 267 | 68 | [
"DDInter1263",
"DDInter1882"
] | Naltrexone | Troleandomycin | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
267,
24,
68
]
],
[
[
267,
63,
1101
],
[
1101,
23,
68
]
],
[
[
267,
24,
1374
],
[
1374,
23,
68
]
],
[
[
267,
24,
710
],
[
710,
24... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abi... |
DB05578 | DB08918 | 330 | 41 | [
"DDInter1566",
"DDInter1059"
] | Ramucirumab | Levomilnacipran | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
330,
24,
41
]
],
[
[
330,
63,
901
],
[
901,
40,
41
]
],
[
[
330,
25,
498
],
[
498,
63,
41
]
],
[
[
330,
64,
1061
],
[
1061,
24,
... | [
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Ramucirumab may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbat... |
DB00852 | DB06335 | 1,445 | 761 | [
"DDInter1545",
"DDInter1646"
] | Pseudoephedrine | Saxagliptin | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1445,
24,
761
]
],
[
[
1445,
21,
28722
],
[
28722,
60,
761
]
],
[
[
1445,
24,
1296
],
[
1296,
63,
761
]
],
[
[
1445,
24,
939
],
[
939,... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is... | Pseudoephedrine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when t... |
DB01142 | DB11796 | 1,264 | 1,612 | [
"DDInter593",
"DDInter786"
] | Doxepin | Fostemsavir | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
1264,
24,
1612
]
],
[
[
1264,
24,
1476
],
[
1476,
62,
1612
]
],
[
[
1264,
62,
112
],
[
112,
23,
1612
]
],
[
[
1264,
63,
1424
],
[
1424... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazol... |
DB00607 | DB11979 | 1,249 | 1,320 | [
"DDInter1256",
"DDInter625"
] | Nafcillin | Elagolix | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1249,
24,
1320
]
],
[
[
1249,
62,
168
],
[
168,
23,
1320
]
],
[
[
1249,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
1249,
63,
79
],
[
79,
... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Nafcillin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"B... | Nafcillin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat... |
DB00850 | DB06335 | 1,630 | 761 | [
"DDInter1432",
"DDInter1646"
] | Perphenazine | Saxagliptin | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1630,
24,
761
]
],
[
[
1630,
6,
8374
],
[
8374,
45,
761
]
],
[
[
1630,
21,
28681
],
[
28681,
60,
761
]
],
[
[
1630,
24,
1491
],
[
1491... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Perphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Perphenazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Perphenazine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Saxagliptin (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01225 | DB09420 | 500 | 1,074 | [
"DDInter645",
"DDInter953"
] | Enoxaparin | Iodide I-123 | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
500,
24,
1074
]
],
[
[
500,
24,
1004
],
[
1004,
63,
1074
]
],
[
[
500,
64,
126
],
[
126,
24,
1074
]
],
[
[
500,
25,
802
],
[
802,
... | [
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],... | Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Enoxaparin may lead to a major life threatening interaction when taken with Warfarin and Warfari... |
DB00404 | DB01114 | 523 | 272 | [
"DDInter54",
"DDInter362"
] | Alprazolam | Chlorpheniramine | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
523,
24,
272
]
],
[
[
523,
24,
849
],
[
849,
63,
272
]
],
[
[
523,
24,
128
],
[
128,
24,
272
]
],
[
[
523,
6,
8374
],
[
8374,
45... | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniram... |
DB01064 | DB01067 | 1,148 | 959 | [
"DDInter987",
"DDInter826"
] | Isoprenaline | Glipizide | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1148,
24,
959
]
],
[
[
1148,
63,
245
],
[
245,
40,
959
]
],
[
[
1148,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1148,
21,
28698
],
[
28698,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB00749 | DB00863 | 59 | 1,194 | [
"DDInter699",
"DDInter1568"
] | Etodolac | Ranitidine | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Minor | 0 | [
[
[
59,
23,
1194
]
],
[
[
59,
62,
1127
],
[
1127,
1,
1194
]
],
[
[
59,
18,
3385
],
[
3385,
57,
1194
]
],
[
[
59,
21,
28701
],
[
28701,
... | [
[
[
"Etodolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Etodolac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nizatidine"
],
[
"Niz... | Etodolac may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine (Compound) resembles Ranitidine (Compound)
Etodolac (Compound) downregulates SDC1 (Gene) and SDC1 (Gene) is downregulated by Ranitidine (Compound)
Etodolac (Compound) causes Discomfort (Side Effect) and Disc... |
DB00816 | DB06203 | 1,674 | 1,002 | [
"DDInter1346",
"DDInter51"
] | Orciprenaline | Alogliptin | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1674,
24,
1002
]
],
[
[
1674,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1674,
21,
28778
],
[
28778,
60,
1002
]
],
[
[
1674,
24,
504
],
[
5... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Orciprenaline (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Alogliptin (Compound)
Orciprenaline may ... |
DB00398 | DB01229 | 79 | 973 | [
"DDInter1702",
"DDInter1378"
] | Sorafenib | Paclitaxel (protein-bound) | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
79,
24,
973
]
],
[
[
79,
24,
310
],
[
310,
63,
973
]
],
[
[
79,
5,
11570
],
[
11570,
44,
973
]
],
[
[
79,
6,
7524
],
[
7524,
45,... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Sorafenib ... |
DB00421 | DB12364 | 443 | 1,421 | [
"DDInter1707",
"DDInter200"
] | Spironolactone | Betrixaban | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
443,
25,
1421
]
],
[
[
443,
24,
971
],
[
971,
24,
1421
]
],
[
[
443,
25,
1456
],
[
1456,
24,
1421
]
],
[
[
443,
24,
714
],
[
714,
... | [
[
[
"Spironolactone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Spironolactone may lead to a major life threatening interaction when taken with Venetoclax and Venetocla... |
DB01278 | DB13913 | 1,021 | 1,536 | [
"DDInter1506",
"DDInter175"
] | Pramlintide | Belladonna | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as ... | Moderate | 1 | [
[
[
1021,
24,
1536
]
],
[
[
1021,
63,
104
],
[
104,
24,
1536
]
],
[
[
1021,
24,
1511
],
[
1511,
24,
1536
]
],
[
[
1021,
63,
104
],
[
104,
... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and... |
DB00741 | DB01259 | 167 | 392 | [
"DDInter885",
"DDInter1024"
] | Hydrocortisone | Lapatinib | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
167,
24,
392
]
],
[
[
167,
6,
4973
],
[
4973,
45,
392
]
],
[
[
167,
18,
20113
],
[
20113,
57,
392
]
],
[
[
167,
21,
29429
],
[
29429,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compou... | Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Hydrocortisone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Lapatinib (Compound)
Hydrocortisone (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapati... |
DB01234 | DB12301 | 1,220 | 907 | [
"DDInter513",
"DDInter585"
] | Dexamethasone | Doravirine | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Major | 2 | [
[
[
1220,
25,
907
]
],
[
[
1220,
24,
1478
],
[
1478,
23,
907
]
],
[
[
1220,
24,
159
],
[
159,
62,
907
]
],
[
[
1220,
25,
1213
],
[
1213,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doravirine"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivaca... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and L... |
DB01064 | DB08899 | 1,148 | 129 | [
"DDInter987",
"DDInter649"
] | Isoprenaline | Enzalutamide | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1148,
24,
129
]
],
[
[
1148,
24,
918
],
[
918,
1,
129
]
],
[
[
1148,
21,
28921
],
[
28921,
60,
129
]
],
[
[
1148,
24,
230
],
[
230,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Isoprenaline (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)
Isoprenaline may cause a moderat... |
DB01128 | DB01259 | 918 | 392 | [
"DDInter204",
"DDInter1024"
] | Bicalutamide | Lapatinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
918,
24,
392
]
],
[
[
918,
6,
8374
],
[
8374,
45,
392
]
],
[
[
918,
21,
28688
],
[
28688,
60,
392
]
],
[
[
918,
23,
271
],
[
271,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Bicalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Bicalutamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Bicalutamide (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Lapatinib (Compound)
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mi... |
DB00748 | DB00985 | 662 | 1,443 | [
"DDInter297",
"DDInter562"
] | Carbinoxamine | Dimenhydrinate | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Moderate | 1 | [
[
[
662,
24,
1443
]
],
[
[
662,
1,
11296
],
[
11296,
1,
1443
]
],
[
[
662,
35,
1376
],
[
1376,
63,
1443
]
],
[
[
662,
24,
537
],
[
537,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound)",
"Bromodiphenhydramine"
],
[
"Bromodiphenhydramine",
... | Carbinoxamine (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenhydramine (Compound) resembles Dimenhydrinate (Compound)
Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and D... |
DB00014 | DB09472 | 521 | 1,383 | [
"DDInter839",
"DDInter1693"
] | Goserelin | Sodium sulfate | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
521,
24,
1383
]
],
[
[
521,
24,
609
],
[
609,
24,
1383
]
],
[
[
521,
24,
1612
],
[
1612,
63,
1383
]
],
[
[
521,
25,
607
],
[
607,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir... |
DB06595 | DB11988 | 1,491 | 270 | [
"DDInter1214",
"DDInter1321"
] | Midostaurin | Ocrelizumab | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1491,
24,
270
]
],
[
[
1491,
63,
134
],
[
134,
24,
270
]
],
[
[
1491,
24,
951
],
[
951,
24,
270
]
],
[
[
1491,
25,
1456
],
[
1456,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and ... |
DB09330 | DB12887 | 985 | 1,598 | [
"DDInter1352",
"DDInter1750"
] | Osimertinib | Tazemetostat | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
985,
24,
1598
]
],
[
[
985,
62,
608
],
[
608,
23,
1598
]
],
[
[
985,
64,
594
],
[
594,
24,
1598
]
],
[
[
985,
24,
738
],
[
738,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Osimertinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
... | Osimertinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Osimertinib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a mo... |
DB00749 | DB09472 | 59 | 1,383 | [
"DDInter699",
"DDInter1693"
] | Etodolac | Sodium sulfate | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
59,
24,
1383
]
],
[
[
59,
24,
1613
],
[
1613,
24,
1383
]
],
[
[
59,
25,
1618
],
[
1618,
24,
1383
]
],
[
[
59,
63,
912
],
[
912,
... | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Etodolac may lead to a major life threatening interaction when taken with Cabozantinib a... |
DB00678 | DB00687 | 240 | 870 | [
"DDInter1095",
"DDInter747"
] | Losartan | Fludrocortisone | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
240,
24,
870
]
],
[
[
240,
24,
1220
],
[
1220,
40,
870
]
],
[
[
240,
63,
251
],
[
251,
40,
870
]
],
[
[
240,
21,
28835
],
[
28835,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludrocor... |
DB00261 | DB00476 | 702 | 109 | [
"DDInter93",
"DDInter608"
] | Anagrelide | Duloxetine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
702,
24,
109
]
],
[
[
702,
25,
847
],
[
847,
1,
109
]
],
[
[
702,
6,
7950
],
[
7950,
45,
109
]
],
[
[
702,
7,
13230
],
[
13230,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atomoxetine"
],
[
"Atomoxeti... | Anagrelide may lead to a major life threatening interaction when taken with Atomoxetine and Atomoxetine (Compound) resembles Duloxetine (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Duloxetine (Compound)
Anagrelide (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulate... |
DB01309 | DB01365 | 1,254 | 280 | [
"DDInter933",
"DDInter1151"
] | Insulin glulisine | Mephentermine | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Moderate | 1 | [
[
[
1254,
24,
280
]
],
[
[
1254,
63,
551
],
[
551,
1,
280
]
],
[
[
1254,
24,
1529
],
[
1529,
1,
280
]
],
[
[
1254,
24,
22
],
[
22,
4... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Mephentermine (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles... |
DB00637 | DB04855 | 1,557 | 540 | [
"DDInter128",
"DDInter602"
] | Astemizole | Dronedarone | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Major | 2 | [
[
[
1557,
25,
540
]
],
[
[
1557,
64,
347
],
[
347,
40,
540
]
],
[
[
1557,
25,
33
],
[
33,
40,
540
]
],
[
[
1557,
6,
8374
],
[
8374,
... | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (C... | Astemizole may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Astemizole may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Astemizole (Compound) binds CY... |
DB00945 | DB01067 | 1,479 | 959 | [
"DDInter20",
"DDInter826"
] | Acetylsalicylic acid | Glipizide | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1479,
24,
959
]
],
[
[
1479,
63,
245
],
[
245,
40,
959
]
],
[
[
1479,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1479,
6,
6017
],
[
6017,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepir... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles... |
DB00087 | DB09052 | 599 | 250 | [
"DDInter41",
"DDInter220"
] | Alemtuzumab | Blinatumomab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
599,
24,
250
]
],
[
[
599,
24,
949
],
[
949,
63,
250
]
],
[
[
599,
63,
305
],
[
305,
24,
250
]
],
[
[
599,
24,
1236
],
[
1236,
2... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxo... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Alemtuzum... |
DB00095 | DB01042 | 66 | 1,307 | [
"DDInter623",
"DDInter1144"
] | Efalizumab | Melphalan | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
66,
24,
1307
]
],
[
[
66,
24,
168
],
[
168,
23,
1307
]
],
[
[
66,
23,
1193
],
[
1193,
62,
1307
]
],
[
[
66,
24,
1683
],
[
1683,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gl... |
DB00445 | DB12015 | 322 | 1,033 | [
"DDInter655",
"DDInter53"
] | Epirubicin | Alpelisib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
322,
24,
1033
]
],
[
[
322,
64,
576
],
[
576,
24,
1033
]
],
[
[
322,
24,
738
],
[
738,
24,
1033
]
],
[
[
322,
25,
1510
],
[
1510,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
... | Epirubicin may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a mod... |
DB00087 | DB08871 | 599 | 36 | [
"DDInter41",
"DDInter666"
] | Alemtuzumab | Eribulin | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
599,
24,
36
]
],
[
[
599,
24,
221
],
[
221,
63,
36
]
],
[
[
599,
24,
563
],
[
563,
24,
36
]
],
[
[
599,
63,
268
],
[
268,
24,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Alemtuzumab may cause a moder... |
DB00465 | DB06822 | 886 | 802 | [
"DDInter1010",
"DDInter1812"
] | Ketorolac | Tinzaparin | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Major | 2 | [
[
[
886,
25,
802
]
],
[
[
886,
24,
222
],
[
222,
24,
802
]
],
[
[
886,
24,
738
],
[
738,
63,
802
]
],
[
[
886,
63,
305
],
[
305,
24,... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Nirapar... |
DB00927 | DB04868 | 1,559 | 478 | [
"DDInter712",
"DDInter1293"
] | Famotidine | Nilotinib | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1559,
24,
478
]
],
[
[
1559,
23,
1468
],
[
1468,
63,
478
]
],
[
[
1559,
7,
3492
],
[
3492,
46,
478
]
],
[
[
1559,
18,
10780
],
[
10780... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
[
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Famotidine (Compound) upregulates E2F2 (Gene) and E2F2 (Gene) is upregulated by Nilotinib (Compound)
Famotidine (Comp... |
DB00973 | DB01098 | 1,149 | 14 | [
"DDInter707",
"DDInter1622"
] | Ezetimibe | Rosuvastatin | Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal vill... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
1149,
24,
14
]
],
[
[
1149,
5,
11596
],
[
11596,
44,
14
]
],
[
[
1149,
6,
8374
],
[
8374,
45,
14
]
],
[
[
1149,
18,
2900
],
[
2900,
... | [
[
[
"Ezetimibe",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Ezetimibe",
"{u} (Compound) treats {v} (Disease)",
"atherosclerosis"
],
[
"atherosclerosis",
"{u} (Disease) is ... | Ezetimibe (Compound) treats atherosclerosis (Disease) and atherosclerosis (Disease) is treated by Rosuvastatin (Compound)
Ezetimibe (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound)
Ezetimibe (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Rosuvastatin (Co... |
DB00349 | DB00366 | 902 | 1,594 | [
"DDInter401",
"DDInter600"
] | Clobazam | Doxylamine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
902,
24,
1594
]
],
[
[
902,
24,
662
],
[
662,
63,
1594
]
],
[
[
902,
21,
28709
],
[
28709,
60,
1594
]
],
[
[
902,
40,
695
],
[
695,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Clobazam (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused b... |
DB06212 | DB09038 | 165 | 1,450 | [
"DDInter1833",
"DDInter636"
] | Tolvaptan | Empagliflozin | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
165,
24,
1450
]
],
[
[
165,
24,
1017
],
[
1017,
63,
1450
]
],
[
[
165,
25,
913
],
[
913,
63,
1450
]
],
[
[
165,
25,
1510
],
[
1510,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Tolvaptan may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cau... |
DB00095 | DB01073 | 66 | 1,488 | [
"DDInter623",
"DDInter745"
] | Efalizumab | Fludarabine | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
66,
24,
1488
]
],
[
[
66,
24,
1426
],
[
1426,
1,
1488
]
],
[
[
66,
24,
975
],
[
975,
63,
1488
]
],
[
[
66,
24,
134
],
[
134,
24,... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Fludarabine (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction t... |
DB00387 | DB00470 | 1,386 | 530 | [
"DDInter1528",
"DDInter601"
] | Procyclidine | Dronabinol | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
1386,
24,
530
]
],
[
[
1386,
24,
1614
],
[
1614,
40,
530
]
],
[
[
1386,
63,
701
],
[
701,
24,
530
]
],
[
[
1386,
24,
1219
],
[
1219,
... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could... |
DB00278 | DB11689 | 291 | 321 | [
"DDInter117",
"DDInter1659"
] | Argatroban | Selumetinib | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
291,
24,
321
]
],
[
[
291,
24,
298
],
[
298,
24,
321
]
],
[
[
291,
25,
498
],
[
498,
24,
321
]
],
[
[
291,
25,
1421
],
[
1421,
6... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
],
[
... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Argatroban may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a mod... |
DB06616 | DB11613 | 594 | 1,519 | [
"DDInter224",
"DDInter1924"
] | Bosutinib | Velpatasvir | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Moderate | 1 | [
[
[
594,
24,
1519
]
],
[
[
594,
63,
1374
],
[
1374,
24,
1519
]
],
[
[
594,
24,
1384
],
[
1384,
24,
1519
]
],
[
[
594,
25,
384
],
[
384,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magal... |
DB01259 | DB08903 | 392 | 996 | [
"DDInter1024",
"DDInter170"
] | Lapatinib | Bedaquiline | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
392,
25,
996
]
],
[
[
392,
6,
8374
],
[
8374,
45,
996
]
],
[
[
392,
21,
29267
],
[
29267,
60,
996
]
],
[
[
392,
62,
112
],
[
112,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Lapatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaquil... | Lapatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Lapatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Bedaquiline (Compound)
Lapatinib may cause a minor interaction that can limit clini... |
DB00674 | DB00738 | 1,516 | 485 | [
"DDInter802",
"DDInter1420"
] | Galantamine | Pentamidine | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1516,
24,
485
]
],
[
[
1516,
6,
12523
],
[
12523,
45,
485
]
],
[
[
1516,
21,
28981
],
[
28981,
60,
485
]
],
[
[
1516,
24,
112
],
[
112... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Galantamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Galantamine (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Pentamidine (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00860 | DB09054 | 891 | 384 | [
"DDInter1513",
"DDInter905"
] | Prednisolone | Idelalisib | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
891,
24,
384
]
],
[
[
891,
24,
555
],
[
555,
23,
384
]
],
[
[
891,
62,
307
],
[
307,
23,
384
]
],
[
[
891,
63,
58
],
[
58,
24,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafin... |
DB01227 | DB06691 | 1,301 | 849 | [
"DDInter1043",
"DDInter1155"
] | Levacetylmethadol | Mepyramine | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Major | 2 | [
[
[
1301,
25,
849
]
],
[
[
1301,
40,
11244
],
[
11244,
1,
849
]
],
[
[
1301,
75,
1594
],
[
1594,
24,
849
]
],
[
[
1301,
63,
272
],
[
272,
... | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepyramine"
]
],
[
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound)",
"Pheniramine"
],
[
"Pheniramine",
"{u} (Compound) resembl... | Levacetylmethadol (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Mepyramine (Compound)
Levacetylmethadol (Compound) resembles Doxylamine (Compound) and Levacetylmethadol may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause a moderate inte... |
DB04845 | DB14975 | 309 | 988 | [
"DDInter1001",
"DDInter1949"
] | Ixabepilone | Voxelotor | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
309,
24,
988
]
],
[
[
309,
63,
63
],
[
63,
24,
988
]
],
[
[
309,
24,
1362
],
[
1362,
24,
988
]
],
[
[
309,
25,
676
],
[
676,
63,... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olapari... |
DB00218 | DB01229 | 1,176 | 973 | [
"DDInter1247",
"DDInter1377"
] | Moxifloxacin | Paclitaxel | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Minor | 0 | [
[
[
1176,
23,
973
]
],
[
[
1176,
6,
3199
],
[
3199,
57,
973
]
],
[
[
1176,
21,
29267
],
[
29267,
60,
973
]
],
[
[
1176,
1,
945
],
[
945,
... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) binds {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Com... | Moxifloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Paclitaxel (Compound)
Moxifloxacin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Paclitaxel (Compound)
Moxifloxacin (Compound) resembles Sparfloxacin (Co... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.